gemigliptin + metformin

**Gemigliptin + metformin** is an oral fixed-dose antidiabetic combination, marketed as **Zemimet SR** and as **Zemiduo SR** in Mexico, for improving glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Gemigliptin is a selective, reversible dipeptidyl peptidase-4 inhibitor that prolongs endogenous incretin activity, while metformin is a biguanide that primarily reduces hepatic glucose production and improves insulin sensitivity. The combination was developed by LG Life Sciences, now LG Chem, and has demonstrated greater HbA1c reduction than either component alone in the 24-week phase III INICOM study. ([lgchem.com](https://www.lgchem.com/product-detail/zemimet-sr-tab?lang=en_US))

Brand names

Zemiduo SRZemimetZemimet SR

Other names

gemigliptin + metformin hydrochloridegemigliptin/metformingemigliptin/metformin hydrochloridegemigliptin/metformin sustained releasemetformin + gemigliptin